Եվրոպական Միություն - էստոներեն - EMA (European Medicines Agency)

pfizer europe ma eeig - krizotiniib - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.

Եվրոպական Միություն - էստոներեն - EMA (European Medicines Agency)

pfizer limited - sunitiniib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastilised ained - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Եվրոպական Միություն - էստոներեն - EMA (European Medicines Agency)

eli lilly nederland b.v. - necitumumab - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - portrazza gemtsitabiini ja tsisplatiini kellel on näidustatud täiskasvanud patsientidel, metastaatilise epidermaalse kasvufaktori retseptori (egfr) lamerakulise mitteväikerakk-kopsuvähi väljendada kes on saanud see tingimus.

Եվրոպական Միություն - էստոներեն - EMA (European Medicines Agency)

janssen-cilag international n.v.   - bosentan (as monohydrate) - scleroderma, systemic; hypertension, pulmonary - antihypertensives, - kopsuarteri hüpertensiooni (pah) ravi, et parandada who funktsionaalse iii klassi patsientide treenimisvõimet ja sümptomeid. efficacy has been shown in: , primary (idiopathic and familial) pah;, pah secondary to scleroderma without significant interstitial pulmonary disease;, pah associated with congenital systemic-to-pulmonary shunts and eisenmenger's physiology. mõningaid parandusi on ka näidanud patsientidel pah who funktsionaalse klassi ii. tracleer on ka märgitud arvu vähendada uue digitaalse haavandid patsientidel süsteemne multiplex ja pidev digitaalne haavand haigus.

Եվրոպական Միություն - էստոներեն - EMA (European Medicines Agency)

astrazeneca ab - osimertinib mesilate - kartsinoom, mitteväikerakk-kopsu - muud antineoplastilised ained, protein kinase inhibiitorid - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

Եվրոպական Միություն - էստոներեն - EMA (European Medicines Agency)

teva b.v. - leflunomiid - arthritis, rheumatoid; arthritis, psoriatic - immunosupressandid - leflunomiidi on näidustatud ravi täiskasvanud patsientidel:aktiivse reumatoidartriidi kui "haigust moduleeriva reumavastased uimasti" (dmard);aktiivse psoriaatilise artriidi. hiljutine või samaaegne ravi hepatotoxic või haematotoxic dmards e. metotreksaat) võib suurendada tõsiste kõrvaltoimete esinemise riski; seetõttu tuleb leflunomiidiravi alustamist nende kasu / riski aspektide osas hoolikalt kaaluda. lisaks sellele üleminek leflunomiidi teise dmard ilma pärast washout menetluse võib suureneda ka risk tõsiste kõrvaltoimete isegi pikka aega pärast lülitus.

Եվրոպական Միություն - էստոներեն - EMA (European Medicines Agency)

pfizer europe ma eeig - inotuzumab ozogamicin - prekursorko-lümfoblastne leukeemia-lümfoom - antineoplastilised ained - besponsa on monoteraapiana retsidiveerunud või tuleohtliku cd22-positiivse b-rakulise prekursori ägeda lümfoblastilise leukeemia (all) täiskasvanute raviks.. täiskasvanud patsientidel, kellel philadelphia kromosoomiga positiivse (ph+) taastekkinud või tulekindlad b-raku eellased kÕik peaks olema ebaõnnestunud ravi vähemalt 1 türosiinkinaasi inhibiitor (tki).

Եվրոպական Միություն - էստոներեն - EMA (European Medicines Agency)

pfizer europe ma eeig - gemtuzumab ozogamicin - leukeemia, müeloidne, äge - antineoplastilised ained - mylotarg on näidustatud kombineeritud ravi daunorubicin (dpl) ja cytarabine (arac) raviks patsientidel vanuses 15 aastat ja üle selle eelnevalt ravimata, de novo cd33-positiivse akuutse müeloidse leukeemia (aml), välja arvatud äge promyelocytic leukeemia (avp).

Եվրոպական Միություն - էստոներեն - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - kartsinoom, mitteväikerakk-kopsu - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Եվրոպական Միություն - էստոներեն - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - leukeemia, lümfotsüütne, krooniline, b-rakk - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.